TWiV 957: Clinical update with Dr. Daniel Griffin

In his weekly clinical update Dr. Griffin discusses human monkeypox virus infection in women and non-binary individuals during the 2022 outbreaks, changes in population immunity against infection and severe disease from SARS-CoV-2 Omicron variants in the United States, updates on COVID-19–related mortality, impact of community masking on COVID-19, effectiveness of the COVID-19 vaccines against hospitalization with Omicron sub-lineages BA.4 and BA.5 in England, cardiovascular outcomes after Tixagevimab and Cilgavimab use for pre-exposure prophylaxis against COVID-19, how Paxlovid is associated with decreased hospitalization rate among adults with COVID-19, inside the mind of an anti-paxxer, and angiotensin receptor blockers for the treatment of COVID-19.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Human monkeypox virus infection in women and non-binary individuals (The Lancet)
• Changes in population immunity against infection and severe disease from variants (Medrxiv)
• Updates on COVID-19 related mortality (CDC)
• Impact of community masking on COVID-19 (Science)
• Effectiveness of the COVID-19 vaccines against hospitalization (The Lancet)
• Cardiovascular outcomes after tixagevimab and cilgavimab use for pre-exposure prophylaxis (CID)
• Bebtelovimab fact sheet for providers (FDA)
• Paxlovid associated with decreased hospitalization among adults (CDC)
• Inside the mind of an Anti-Paxxer (The Atlantic)
• Paxlovid patient eligbiliity screening checklist (FDA)
• Angiotensin receptor blockers for the treatment of COVID-19 (BMJ)
• Long COVID treatment research study (Stanford)
• HHS long COVID study (pdf)
• Biden administration requests long COVID fu
• Contribute to our MicrobeTV fundraiser at PWB
• Dr. Griffin's treatment guide (pdf)
• Letters read on TWiV 957
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]